Patient enrollment is complete in a phase 1 clinical trial evaluating EYP-1901 to treat wet age-related macular degeneration, according to a press release from EyePoint Pharmaceuticals.
The ongoing open-label, 12-month, dose-escalation DAVIO trial is evaluating EYP-1901 as a twice-yearly intravitreal therapy in patients with wet AMD who were responsive to previous anti-VEGF treatments, the release said.
“EYP-1901 represents an exciting potential advancement for the treatment of wet AMD as a twice-yearly therapy using our proven Durasert technology that provides reliable, sustained,